These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19542717)

  • 1. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].
    Ono C; Yamagami M; Kamatani R; Yamamoto M; Mukouyama T; Sugimoto M; Suzuki T; Kamo N; Seki N; Eguchi K; Ikeda T
    Gan To Kagaku Ryoho; 2012 May; 39(5):777-81. PubMed ID: 22584330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation].
    Suga Y; Kumazaki M; Nishigami J; Takeda K; Kawagishi A; Ishizaki J; Inokuchi M; Miyamoto K; Arai K
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):93-6. PubMed ID: 19151570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin.
    Nagata K; Egashira N; Yamada T; Watanabe H; Yamauchi Y; Oishi R
    Support Care Cancer; 2012 May; 20(5):951-5. PubMed ID: 21519948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis.
    Roberts R; Hanna L; Borley A; Dolan G; Williams EM
    Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13114. PubMed ID: 31148328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vasculitic condition following instillation of epirubicin hydrochloride in an outpatient chemotherapy].
    Nakazawa Y; Matsubara Y; Suzuki M; Asako E; Honda A
    Gan To Kagaku Ryoho; 2005 Dec; 32 Suppl 1():24-6. PubMed ID: 16422479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
    Monden M; Nakamura H; Yayoi E; Monden T; Ohi H; Arisawa J; Masuzawa M; Shimizu T; Tomono N; Seki K; Nakao N; Todo A; Inoue Y; Sakon M; Ohsaki Y; Hosoki T
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1713-9. PubMed ID: 9757197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk Factors for Oxaliplatin-Induced Phlebitis and Venous Pain, and Evaluation of the Preventive Effect of Preheating with a Hot Compress for Administration of Oxaliplatin].
    Nakauchi K; Kawazoe H; Miyajima R; Waizumi C; Rokkaku Y; Tsuneoka K; Higuchi N; Fujiwara M; Kojima Y; Yakushijin Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1397-400. PubMed ID: 26602398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery.
    Chang LC; Wu SC; Tsai JW; Yu TJ; Tsai TR
    Int J Pharm; 2009 Jul; 376(1-2):195-203. PubMed ID: 19439169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of phlebitis associated with cefazolin and cephalothin.
    Cole DR
    Int J Clin Pharmacol Biopharm; 1976 Jul; 14(1):75-7. PubMed ID: 789268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin and its metabolites levels in experimental liver metastases after different administration routes.
    Bacchetti S; Pasqual E; Cagol PP
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):181-5. PubMed ID: 16767928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical re-evaluation of effects of different treatments to prevent from phlebitis induced by Chansu injection].
    Zhao Y; Hao Z; Zhang H; Shi J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2803-6. PubMed ID: 22292370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy induced phlebitis experienced by women with breast cancer following administration of epirubicin using a volumetric infusion pump: an observational study.
    Williams N; Williams EM; Roberts R
    Eur J Oncol Nurs; 2023 Jun; 64():102322. PubMed ID: 37141665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious allergic reaction to administration of epirubicin.
    Oltmans R; van der Vegt SG
    Neth J Med; 2003 Jun; 61(6):226-7. PubMed ID: 12948166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
    Okumura A; Oishi N; Kaji K; Imamura T; Fuse H
    J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations on prevention of phlebitis and venous pain from intravenous prostaglandin E(1) administration by adjusting solution pH: in vitro manipulations affecting pH.
    Kohno E; Nishikata M; Okamura N; Matsuyama K
    Yakugaku Zasshi; 2008 Jan; 128(1):111-5. PubMed ID: 18176061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peripheral venous catheters: incidence of phlebitis and its determining factors].
    Regueiro Pose MA; Souto Rodríguez B; Iglesias Maroño M; Outón Fernández I; Cambeiro Nuñez J; Pértega Díaz S; Pita Fernández S
    Rev Enferm; 2005 Oct; 28(10):21-8. PubMed ID: 16304830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-associated flare reactions.
    Curran CF; Luce JK; Page JA
    Oncol Nurs Forum; 1990; 17(3):387-9. PubMed ID: 2342972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
    Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
    Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.